Latest Posters
Poster
Reporter Bioassays to Assess Therapeutic Antibodies for Immunotherapy Programs
Immunotherapy, also called biologic therapy or biotherapy, stimulates certain parts of the immune system to fight diseases such as cancer. Important drug targets in immunotherapy include: Co-inhibitory receptors, such as PD-1/PD-L1, CTLA-4, LAG3, Tim3; and co-stimulatory receptors, such as GITR, CD40, OX40, 4-1BB.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.
Poster
Development of a Robust Reporter-based T cell Activation Assay for Therapeutic Biologics in Immunotherapy
Jurkat T-cells stably expressing luciferase reporter driven by IL2 promoter or NFAT-RE, are used as effector cells. Tumor cell lines endogenously expressing cancer antigen are used as antigen presenting cells (APC). By co-cultivating the two cell lines in the presence of CD3 bispecific antibody, TCR/CD3 is activated in Jurkat effector cells. Luciferase activity is up regulated through IL-2 promoter or NFAT-RE activation.
Poster
CellTiter-Glo® 2.0: A Novel Luminescent Cell Viability Assay with Greatly Enhanced Storage Stability
Here we report on the attributes of a novel ATP detection reagent for cell viability with all of the assay performance of the previous CellTiter-Glo® Reagent, but now with markedly enhanced stability as a single component in a liquid format. These new features provide for much greater ease-of-use in that storage of the reagent at 4°C eliminates the requirement for reagent thawing and minimizes temperature equilibration time.
Poster
Better Cell-Based Assays for Anti-CTLA-4, Anti-PD-1/PD-L1, and Bispecific Immunotherapy Drug Studies
Here we report the development of a panel of robust reporter assays to measure the potencies for biologics in immunotherapy. These assays reflect mode of action and can serve as valuable tools in immunotherapy drug development and discovery.
Poster
An IgG Cleaving Protease from S equi with Improved Activity Against Mouse IgGs
Here we have expressed and purified a modified recombinant IdeZ, and show that it has significantly improved activity against mouse IgG2a and IgG3 subclasses when compared to IdeS. We also demonstrate the use of IdeZ in LC-MS workflows for human and mouse IgG characterization.
Poster
A Simple Plate Based Assay Using pH Sensor Dye to Screen for Internalizing Antibody
Receptor mediated internalization is a key mechanism of action (MOA) for antibody drug conjugates (ADCs). However, current methods of studying antibody internalization have several limitations including: 1) A multistep process not suitable for screening; 2) Low signal-to-background ratios; 3) Not suitable for kinetic measurements. We have developed a method that mitigates problems associated with traditional internalization assays.
Poster
Study Of The Active Bacterial Community In Two Membrane Bioreactors
In this work, bacterial communities from two MBR systems treating leachates were evaluated using the 16S rRNA metagenomics approach, with and without a viability dye (Propidium Monoazide, PMA).
Poster
Characterization of Protein and Protein Aggregates using Temperature-controlled Hollow-Fiber Flow-FFF
Reproducibilty Improvements in Field Flow Fractionation can be achieved on two fronts. Instrument design and control, the system used in for this poster is does not require flow controllers or switching valves and there for produces the same conditions in every case. Fractionater design, the design of the cartridges used in this poster maintain excellent conditions to maintain constant pressure at the membrane removing unwanted effects of sale relaxation above the membrane s
Poster
Development of a Novel Xeno-free Medium for Feeder-free Culture of Human Stem Cells
A new xeno-free medium (ReproXFTM) has been developed for feeder-free culture of stem cells.
Poster
Non-disruptively Count and Quantify Fluorescent iPS Colonies During Secondary Reprogramming: 7 min per 6-well Plate, Dual-fluorescence Whole Well Imaging Cytometry
Nexcelom’s Celigo imaging cytometer has been applied to provide automated, rapid assessment of iPS reprogramming.
Advertisement